Innovations in cancer immunotherapy: chimeric antigen receptor T-cell therapy (CAR-T).

Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma. The patient is monitored for cytokine release syndrome (CRS) and immune effector cell-associated neurologic syndrome for up to 28 days and monitored long term for B-cell hypoplasia, hypogammaglobulinemia, cytopenias and opportunistic infections. Most patients with relapsed refractory high-grade B-cell lymphoma and B-cell acute lymphoblastic leukemia have progression-free and overall survival rates better than historical controls, and a small proportion are cured. Chimeric antigen receptor T-cell therapy (CAR-T) is a targeted, gene-edited cell therapy for cancer that is approved in Canada for relapsed or refractory high-grade B-cell lymphoma and B-cell acute lymphoblastic leukemia. [Extracted from the article]